For research use only. Not for therapeutic Use.
Periplocymarin, a cardiac glycoside isolated from Periploca sepium and Periploca graeca, is a potential anti-cancer compound[1][2].
Periplocymarin inhibits proliferation of PC3, U937, HCT-8, Bel-7402, BGC823, A549, and A2780 cell lines in vitro with IC50 values of 0.02-0.29 µM[2].
Catalog Number | R072662 |
CAS Number | 32476-67-8 |
Synonyms | 3-[(3S,5S,8R,9S,10R,13R,14S,17R)-5,14-dihydroxy-3-[(2R,4S,5R,6R)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy-10,13-dimethyl-2,3,4,6,7,8,9,11,12,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]-2H-furan-5-one |
Molecular Formula | C30H46O8 |
Purity | ≥95% |
InChI | InChI=1S/C30H46O8/c1-17-26(32)23(35-4)14-25(37-17)38-19-5-9-27(2)21-6-10-28(3)20(18-13-24(31)36-16-18)8-12-30(28,34)22(21)7-11-29(27,33)15-19/h13,17,19-23,25-26,32-34H,5-12,14-16H2,1-4H3/t17-,19+,20-,21+,22-,23+,25+,26-,27-,28-,29+,30+/m1/s1 |
InChIKey | XRWQBDJPMXRDOQ-YUUDFPFBSA-N |
SMILES | CC1C(C(CC(O1)OC2CCC3(C4CCC5(C(CCC5(C4CCC3(C2)O)O)C6=CC(=O)OC6)C)C)OC)O |
Reference | [1]. Martey ON, et al. Periplocymarin is a potential natural compound for drug development: highly permeable with absence of P-glycoprotein efflux and cytochrome P450 inhibitions. Biopharm Drug Dispos. 2014 May;35(4):195-206. [2]. Redox-responsive PEGylated self-assembled prodrug-nanoparticles formed by single disulfidebond bridge periplocymarin-vitamin E conjugate for liver cancer chemotherapy. Drug Deliv. 2017 Nov;24(1):1170-1178. |